NOVELSTEM Stock OTC Markets

NSTM

US4362331005

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 17:59:07 05/10/2021 +03			5-day change	1st Jan Change
0.2700 ^USD	+7.57%		-3.50%	+44.75%

05-15	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

NovelStem International Corp. is a development stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ€™ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	641K 559K 518K 485K 909K 60.51M 915K 6.14M 2.38M 29.79M 2.41M 2.36M 103M	P/E 2024	-0.11x	P/E 2025	0.18x
Enterprise Value	2.54M 2.22M 2.05M 1.92M 3.61M 240M 3.63M 24.38M 9.45M 118M 9.55M 9.35M 410M	EV / Sales 2024	398,132,333x	EV / Sales 2025	-
Free-Float	38.73%	Yield 2024 *	-	Yield 2025	-

05-15	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
11-12	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/08/25	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/05/25	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
08/04/25	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/04/25	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
15/11/24	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
15/08/24	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
15/05/24	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/04/24	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
17/11/23	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

20/05/25	NovelStem Announces Material Developments and Strategic Repositioning of the Company	AQ
31/03/23	NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
17/01/23	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/10/22	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K)	AQ

Manager	Title	Age	Since
Christine Jenkins DFI	Director of Finance/CFO	63	29/09/2022
Jan Loeb PSD	President	67	13/01/2023

Director	Title	Age	Since
David Seltzer BRD	Director/Board Member	66	-
Mitchell Rubenstein CHM	Chairman	72	22/01/1993
Jan Loeb CHM	Chairman	67	01/07/2018

NOVELSTEM Stock OTC Markets

Stocks

NSTM

US4362331005

Biotechnology & Medical Research

Valuation: NOVELSTEM

Latest news : NOVELSTEM

Press Releases: NOVELSTEM

Quotes and Performance

Managers and Directors: NOVELSTEM

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELSTEM	+7.57%	-3.50%	-	-	641K
ARGENX SE	+1.44%	-1.25%	+63.52%	+114.88%	54.44B
WUXI APPTEC CO., LTD.	+4.60%	+5.82%	+56.35%	+43.04%	45.8B
BIONTECH SE	-1.44%	+1.51%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-0.95%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	+2.94%	+24.02%	-35.05%	16.25B
GENMAB A/S	+0.58%	+1.08%	+16.73%	-38.06%	15.34B
EXELIXIS, INC.	-1.01%	-2.97%	+27.42%	+171.92%	13.05B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+5.43%	+21.37%	-	12.37B
PHARMAESSENTIA CORPORATION	+4.95%	+13.49%	+121.11%	+249.05%	12.47B
Average	+2.03%	+2.19%	+34.88%	+108.19%	23.72B
Weighted average by Cap.	+1.63%	+1.38%	+39.56%	+98.70%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.02 1.13 0.02 0.11 0.04 0.56 0.05 0.04 1.94	-
Net income	-3.23M -2.82M -2.61M -2.44M -4.58M -305M -4.61M -30.97M -12M -150M -12.14M -11.88M -521M	2.38M 2.08M 1.92M 1.8M 3.37M 225M 3.39M 22.8M 8.84M 111M 8.93M 8.74M 384M
Net Debt	4.41M 3.85M 3.56M 3.34M 6.25M 416M 6.29M 42.27M 16.38M 205M 16.56M 16.21M 711M	1.9M 1.66M 1.54M 1.44M 2.7M 180M 2.71M 18.23M 7.07M 88.41M 7.15M 6.99M 307M